Number of Ophthalmic Drugs in Pipeline is Extremely High, accoridng to GBI Research Study Available at MarketPublishers.com
20 Dec 2016 • by Natalie Aster
LONDON – With the existence of a set of approved treatments of eye conditions, there are still presently no curative treatments for any of these therapeutic indications. Particularly, there are robust unmet needs remaining many aspects of age-related macular degeneration (AMD) and glaucoma care, which can potentially result in blindness if not treated adequately.
Though there is a high rate of failure and uncertainty within the research and development of pharmaceutical drugs, there is a good deal of interest in the progress of ophthalmology. All in all, there are more 700 drug products under active development in the ophthalmology therapy domain, making it one of the biggest therapy area pipelines.
Though two thirds of drugs in development for ophthalmic conditions are at the discovery or pre-clinical stage of the development process, the number of medications in the pipeline is extremely large, which creates huge potential for blockbuster drug products to come into the market.
New market research study “Ophthalmology Drug Development Pipeline Review, 2016” created by GBI Research offers a comprehensive, detailed guide to the ophthalmology therapeutics universe.
The report provides detailed information about the pipeline development space for glaucoma, AMD, diabetic macular edema (DME), diabetic retinopathy and dry eye syndrome (DES), from discovery up to the pre-registration stage. The study presents accurate insights into the products by phase of development, RoA, molecular target, MoA and molecule type. It offers a listing of all products in development, with dormant and discontinued projects included. Additionally, the research publication gives an insightful overview of the leading players engaged in the respective product development, and casts light on the latest updates and press releases in the domain.
More research publications by our market research partner are available at its page.